Novavax

Historical price data

Novavax is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel vaccines to prevent serious infectious diseases. Its core technology platform combines recombinant nanoparticle antigens with its patented saponin-based Matrix-M™ adjuvant to stimulate robust immune responses. The company achieved a major milestone with the global authorization of its COVID-19 vaccine and is now advancing a diversified pipeline targeting respiratory viruses. Novavax's strategic direction involves expanding the utility of its platform, pursuing combination vaccines, and establishing its commercial presence.

A proprietary vaccine platform combining recombinant nanoparticle protein antigens with a patented saponin-based Matrix-M™ adjuvant, designed to produce robust and broad immune responses.

52 drugs in pipeline, 17 in Phase 3

Total raised: $385.6M

Novavax faces intense competition from giants like Pfizer, Moderna, GSK, and Sanofi in the COVID-19 and influenza markets. Its differentiation lies in its protein-based nanoparticle platform and Matrix-M adjuvant, which may offer advantages in tolerability and immune response profile. However, it must overcome competitors' significant commercial scale, faster development cycles (for mRNA), and entrenched market positions.